AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01771133 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention group
Description: The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
Study NCT04293159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG (Enterolactis duo®)
Description: Lactobacillus casei DG (Enterolactis duo®)
Study NCT06103656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo
Description: Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
Study NCT06103656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Omalizumab
Description: 4 months course, starting 2 months pre-OIT through the 2 month build-up phase
Study NCT04470856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test (EEOT)
Description: An occlusion manoeuvre during the end of expiration for 20 seconds
Study NCT01275170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7655
Description: 125 mg intravenous (IV) over 30 minutes as a single dose
Study NCT02007356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN-γ positive selected T-cells
Study NCT00431457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an intracranial electrode
Description: Implantation of an intracranial electrode will be followed.
Study NCT00431457 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Implantation of an intracranial electrode
Description: Implantation of an intracranial electrode will be followed.
Study NCT00431457 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: amygddohyppocampertomy
Description: Resective surgery
Study NCT03773757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IN-PEACE Dementia Care Coordination
Description: Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
Study NCT02572050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Gastrectomy with D2 LND
Description: Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
Study NCT03063827 — intervention group
Intervention type: DRUG
Intervention: OnabotulinumtoxinA 200 UNT
Description: Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
Study NCT03063827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urothelial sensory protein levels
Description: Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
Study NCT03056690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0819
Description: Oral capsule
Study NCT03056690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT01585766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 30 MG-IV
Description: Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
Study NCT01585766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 60 MG-SC
Description: Participants received SC injection of 60 mg MEDI-551 on Day 1.
Study NCT01585766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO-IV-SC
Description: Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
Study NCT01585766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 100 MG-IV
Description: Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
Study NCT01585766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 300 MG-SC
Description: Participants received SC injection of 300 mg MEDI-551 on Day 1.
Study NCT01585766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 600 MG-IV
Description: Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
Study NCT03967470 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bacterial spray
Description: Bacterial spray containing bacteria that do not cause underarm malodor
Study NCT03967470 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacterial spray
Description: Bacterial spray containing bacteria that do not cause underarm malodor
Study NCT00203450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonegran
Description: zonisamide
Study NCT00203450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study NCT02690961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Study NCT02690961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo multiple doses
Study NCT01701258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
Study NCT01701258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose placebo capsule during the fMRI session only
Study NCT05630937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-01940153E
Description: Route of administration: intravenous (IV) solution
Study NCT00177424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
Study NCT00177424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study NCT00911014 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
Study NCT02173756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine gel
Description: 1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
Study NCT02173756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
Study NCT03669965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth
Study NCT03837899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab / Tremelimumab Combination Therapy
Description: Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase.
Study NCT01275170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose
Study NCT01172548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT02751151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: have Levulan Kerastick (aminolevulinic acid) solution
Description: Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
Study NCT04482569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
Study NCT01275170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine caplet, single 200 mg dose, orally
Study NCT01275170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam hcl syrup single 2.0 mg dose by mouth.
Study NCT01275170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
Study NCT04873947 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: The investigational device will be placed on the finger of the left or right hand per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.
Study NCT02866305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS bullectomy and mechanical pleuradesis.
Description: Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
Study NCT02866305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube insertion
Description: Conventional chest tube insertion.
Study NCT02866695 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ingenol mebutate gel 0.015%
Description: ingenol mebutate gel 0.015% to be applied on treatment area
Study NCT02866305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural
Description: All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
Study NCT02399410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perioperative chemotherapy plus bevacizumab
Description: preoperative and postoperative combination chemotherapy with bevacizumab
Study NCT02399410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
Study NCT02399410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Oxaliplatin
Description: Pump-driven intraperitoneal administration of oxaliplatin
Study NCT03520582 — intervention group
Intervention type: DEVICE
Intervention: Tube placement
Description: Placement of enteral feeding tubes
Study NCT03525769 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FibroTouch
Description: FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging.
Study NCT00696891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 3-dose intramuscular injection
Study NCT00696891 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT02866305 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-resolution Computer Tomography
Description: All participants included in this study had a HRCT performed.
Study NCT00345969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Testosterone gel (1%)
Description: Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
Study NCT00345969 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised exercise training
Description: Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
Study NCT00345969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise training
Description: Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
Study NCT00991146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab
Study NCT00329758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: 20 mg oral, during 10 days
Study NCT00329758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01294709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant
Study NCT01294709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to telcagepant
Study NCT03693235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bending angle of a lightwand
Description: For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
Study NCT03572049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA itraconazole
Description: SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
Study NCT04290364 — intervention group
Intervention type: OTHER
Intervention: Palliative care
Description: The patients in the prospective part of the study are seen on home-visits and offered standard palliative care within three weeks of diagnosis.
Study NCT03572049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional itraconazole
Description: Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
Study NCT04189536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Intervention
Description: Delivery of text messages will use the Rip Road Mobile platform.
Study NCT04054011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid
Description: Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
Study NCT00648739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samalizumab
Description: Samalizumab is a humanized anti-CD200 monoclonal antibody.
Study NCT03125239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
Study NCT03125239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2874455
Description: This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
Study NCT02387723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose derived stem cells (CSCC_ASC)
Description: Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
Study NCT03390010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Study NCT03390010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Study NCT02788955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Study NCT02788955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counselling
Study NCT02788955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Protein
Study NCT02788955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Protein
Study NCT00572910 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (PBO)
Description: Group 6: Placebo (PBO / PBO / PBO)
Study NCT00572910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA
Study NCT00572910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA
Study NCT00572910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA
Study NCT00572910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA
Study NCT00572910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA
Study NCT02173132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine
Study NCT02173132 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03099161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preladenant
Description: Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
Study NCT03099161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as IV infusion on Day 1 of each 21-day cycle
Study NCT01654211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: single iv infusion
Study NCT01654211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: single oral dose
Study NCT01654211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single iv infusion
Study NCT01654211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses
Study NCT01654211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ritonavir
Description: oral doses
Study NCT01654211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: oral doses
Study NCT04681001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal spray
Description: application of nasal spray into nostrils and mouth
Study NCT04681001 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray
Description: application of nasal spray into nostrils and mouth
Study NCT01412307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle